Function is more important. Not just having muscles, but what the patient can do with them.
In the corridors of cancer care, a quiet revolution is unfolding: researchers from São Paulo and Harvard have found that what a lung cancer patient can do with their body matters more than how much body they have left. Studying 55 patients with advanced non-small cell lung cancer, scientists discovered that simple acts — walking a hallway, rising from a chair — predicted survival more reliably than muscle mass alone. Two blood markers, serine and M22G, have also emerged as potential guides for identifying who will respond to chemotherapy. The findings invite medicine to reconsider what resilience truly looks like in the face of a disease that claims more lives than almost any other.
- Advanced lung cancer patients arrive already diminished — some having lost thirty kilograms — as cachexia quietly consumes muscle and fat while the clock runs down to a median survival of ten months.
- The long-held assumption that muscle mass signals a patient's capacity to endure treatment has been overturned: function, not volume, is what predicts who lives longer.
- Two plasma substances — serine and M22G — have been identified as potential biomarkers that could tell clinicians in advance which patients are most likely to benefit from chemotherapy.
- Tumors appear to flood the bloodstream with inflammatory metabolites that impair how muscle cells consume oxygen, explaining why some wasted patients still outperform expectations while others with more mass falter.
- Researchers are now asking whether structured physical exercise during chemotherapy could break the cachexia cycle itself — a question that, for patients with months to live, carries enormous weight.
A patient with advanced lung cancer walks three meters down a hallway and back. She sits and stands ten times. She walks for six minutes. These unremarkable movements have become, for researchers at the University of São Paulo and Harvard Medical School, a surprisingly powerful window into survival.
Studying 55 patients with metastatic non-small cell lung cancer — mostly men with long smoking histories who arrived severely debilitated — the team found something counterintuitive: performance in basic physical tests predicted survival far better than muscle mass. Published in the European Journal of Clinical Investigation, the finding challenges a foundational assumption in oncology. "Function is more important," said first author Willian das Neves Silva. "Not just having muscles, but what the patient can do with them."
The researchers also identified two blood plasma substances — serine, an amino acid involved in muscle function, and M22G — as potential biomarkers for predicting chemotherapy response. Their theory is that tumors trigger inflammation that floods the body with metabolites damaging muscle cells and reducing their oxygen consumption. This explains why some severely wasted patients still performed well: their depleted muscle retained its functional quality. A follow-up study confirmed the pattern, finding that intramuscular fat and food aversion also predicted worse outcomes.
Lung cancer kills more men than any other cancer and ranks second in women, with advanced cases carrying a median survival of roughly ten months. The next research phase will deploy artificial intelligence to search for additional biomarkers and, crucially, test whether exercise during chemotherapy can reverse cachexia and strengthen the body's response to treatment. For patients measured in months, the answer could fundamentally reshape how that time is lived.
A patient with advanced lung cancer walks three meters down a hallway, turns around, and walks back. She sits down and stands up ten times. She walks for six minutes. These simple movements—the kind most people perform without thinking—have become a window into whether she will survive her disease.
Researchers at the University of São Paulo and Harvard Medical School studied 55 patients with metastatic non-small cell lung cancer, the most common form of the disease, and found something counterintuitive: how well patients performed in basic physical tests predicted their survival far better than how much muscle they had. The study, published in the European Journal of Clinical Investigation, upends a long-held assumption in oncology that muscle mass itself is the key measure of a cancer patient's resilience.
The patients in the study, mostly men who had smoked for decades, arrived at the São Paulo State Cancer Institute severely debilitated. Some had lost thirty kilograms in the previous six months. Many showed signs of cachexia, the wasting syndrome that strips away muscle and fat tissue as the body consumes itself. Yet when researchers put them through physical tests—standing, walking, sitting, and in some cases cycling on an ergometer while wearing an oxygen mask—they discovered that patients with better performance in these tests lived longer, regardless of their overall physical condition or muscle mass. "Function is more important," said Willian das Neves Silva, the study's first author. "Not just having muscles, but what the patient can do with them."
The finding matters because it changes how doctors might approach treatment. If a patient can perform well in these simple tests, physicians have evidence that the patient has the physiological capacity to endure chemotherapy. The research team also identified two substances in patients' blood plasma—serine and M22G—that appear to predict which patients will respond best to chemotherapy. Serine, a nonessential amino acid involved in protein synthesis and muscle function, circulates at elevated levels in cancer patients, and its reduction has been proposed as a potential treatment target.
Lung cancer kills more men than any other cancer and ranks second in women. Non-small cell lung cancer accounts for eighty percent of all cases. The median survival for advanced patients is roughly ten months. More than ninety percent of cases are linked to smoking. The patients in this study were typically in their sixties, with long smoking histories and little time left.
The researchers believe that tumors trigger an inflammatory process that floods the bloodstream with metabolites—byproducts of cellular activity—that damage muscle cells and reduce their ability to consume oxygen. This explains why some severely wasted patients could still perform well: their remaining muscle, though depleted, retained function. In contrast, patients with poor performance in the physical tests showed impaired oxygen consumption, a sign that their cells were struggling at a metabolic level.
A follow-up analysis, published in JCSM Communications, examined a second group of patients with even worse physical performance and found that inflammation, food aversion, and intramuscular fat—fat deposits within muscle tissue itself, a marker of poor muscle quality—all predicted worse survival. The pattern held: quality and function mattered more than quantity.
The next phase of research will use artificial intelligence to reanalyze all patient data in search of additional biomarkers, and will test whether physical exercise during chemotherapy can reverse the cachexia cycle and improve outcomes. The researchers are asking a fundamental question: if poor muscle function predicts poor survival, can improving that function through exercise make cells more resistant to inflammation and boost the cancer-fighting power of chemotherapy itself? For patients with ten months to live, the answer could reshape how they spend their remaining time.
Citações Notáveis
Function is more important. Not just having muscles, but what the patient can do with them. Physical fitness matters more than muscle mass.— Willian das Neves Silva, first author of the study
Patients with better physical performance live longer, and this has nothing to do with their overall condition.— Willian das Neves Silva
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that function beats muscle mass? Couldn't doctors just measure muscle and get the same answer?
Because muscle mass is static—it's a snapshot. Function tells you what's actually happening inside the cells. A patient can have lost thirty kilograms and still have muscles that work. Another patient with more muscle might have cells that are metabolically broken. The second patient will die sooner.
So you're saying the tumor is poisoning the muscle cells themselves, not just shrinking them?
Exactly. The inflammation from the tumor releases metabolites into the bloodstream that damage how muscle cells use oxygen. It's like the cells are being slowly suffocated from the inside. The physical tests reveal that damage before it shows up on a scan.
What does serine have to do with it?
Serine is an amino acid the body needs for muscle function. But in cancer patients, too much serine circulates in the blood, and that excess is linked to tumor growth. If you could lower serine levels, you might slow the cancer and protect the muscle at the same time.
Can doctors use these physical tests right now, or is this still experimental?
The tests themselves are simple—anyone can do them. But the research is still new. What's experimental is using the tests to predict which patients can handle chemotherapy and which ones need a different approach. That's the next step.
If exercise could reverse cachexia, would that change treatment?
It could be transformative. Right now, doctors treat the cancer and hope the patient survives the side effects. If exercise could strengthen muscle function and make cells more resistant to inflammation, it becomes part of the cure, not just something patients do on the side.
How much time do these patients actually have?
Ten months on average. So every week matters. If a simple walking test can tell doctors whether a patient can tolerate aggressive chemotherapy, that's not just data—that's time.